Molecular and Genetic Characterization of Inborn Errors of Immunity (R21 Clinical Trial Not Allowed)

Funding Opportunity PAR-19-079 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to advance the experimental validation and functional characterization of genetic variants in coding or non-coding genomic regions that result in inborn errors of immunity/primary immunodeficiency diseases and to elucidate the molecular, cellular, and immunological mechanisms of these disorders. Understanding the genetic basis of primary immunodeficiency disorders is essential for their diagnosis, prognosis, and the development of precision therapeutics. (Source: NIH Funding Opportunities (Notices, PA, RFA))

from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2E1rUr4